Tag: Schizophrenia
Risk for Schizophrenia Increased With ED Visits Involving Hallucinogen Use
Increased risk for SSD seen within three years for individuals with ED visit for hallucinogen use compared with ED visits for alcohol, cannabis
Transcranial Direct Current Stimulation Safe, Effective for Tardive Dyskinesia
Findings seen among patients hospitalized long term for schizophrenia
FDA Approves Cobenfy for Adults With Schizophrenia
Approval marks first new class of treatment in decades and the first muscarinic agonist
High Rate of Comorbid Mental Health Disorders Seen in Schizophrenia
Low rates of treatment observed, with only 26 percent receiving minimally adequate mental health treatment
FDA Approves New Kind of Drug for Schizophrenia
Childhood BMI Linked to Increased Risk for Schizophrenia
Direct causal effect of childhood BMI on schizophrenia seen in Mendelian randomization analyses, independent of adulthood BMI
SNP rs13194504 AA Genotype Linked to Severity of Tardive Dyskinesia
AA genotype linked to reduced severity, but not occurrence, of TD; no association seen for rs210133 with TD occurrence, severity
Electroconvulsive Therapy Safe, Effective for Range of Serious Mental Illnesses
Serious complications are rare, with confusion and cognitive side effects most common
Probiotic, Vitamin D Supplementation Tied to Benefits With Schizophrenia
Improvements seen in cognition, cholesterol, blood sugar, and C-reactive protein
Schizophrenia Linked to Increased Risk for Subsequent CVD Events
Association between schizophrenia and cardiovascular disease events more pronounced in women than men
